^
    Back
    Association details:
    Biomarker:MUC1 expression
    Cancer:Ovarian Cancer
    Drug:P-MUC1C-ALLO1 (MUC1-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2021
    Title:

    123 P-MUC1C-ALLO1: A fully allogeneic stem cell memory T cell (TSCM) CAR-T therapy with broad potential in solid tumor

    Published date:
    11/09/2021
    Excerpt:
    P-MUC1C-ALLO1 is an allogeneic TSCM CAR-T therapy that has a potential to treat multiple MUC1-expressing indications. P-MUC1C-ALLO1 displayed specificity for tumor vs. normal cells as well as in vivo efficacy against xenograft models of breast and ovarian cancer.
    DOI:
    http://dx.doi.org/10.1136/jitc-2021-SITC2021.123
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2020
    Title:

    120 P-MUC1C-ALLO1: An allogeneic car-t for multiple solid tumor indications

    Published date:
    11/09/2020
    Excerpt:
    P-MUC1C-ALLO1 is Poseida’s allogeneic CAR TSCM product that has a potential to treat multiple MUC1-expressing indications. P-MUC1C-ALLO1 displayed in vitro specificity for tumor vs normal cells, and in vivo efficacy against xenograft models of breast and ovarian cancer.
    DOI:
    10.1136/jitc-2020-SITC2020.0120